… The reduction in reactive oxygen species caused by xanthine oxidase inhibition [93] may …
with elamipretide demonstrated improved left ventricular (LV) contractile function and a smaller …

… of hypertensive patients with or without left ventricular hypertrophy (NCT03088514) and …
adaptation to a dilating and failing ventricle, as seen in dilated cardiomyopathy. The nature …

… kinase G activity in adjacent cardiomyocytes, causing left ventricular (LV) dysfunction. …
Xanthine oxidoreductase inhibition has been demonstrated to improve endothelial function by …

… nicorandil was able to alter xanthine oxidase activity using a … induced left ventricular
dilation, cardiac dysfunction and … DMD associated cardiomyopathy with PDE 5 inhibition may …

… not in the non-infarct region of the left ventricle (LV), was increased in the … dilated
cardiomyopathy. The suppression of XO activity by an XO inhibitor was found to prevent LV …

… Heart tissues (~2 mm3) from the free wall of the left ventricle were fixed in 2.5%
glutaraldehyde (preparation for 100 ml solution: 50 ml of 0.2 M phosphate buffer, 10 ml of 25% …

… significantly attenuated LV dilatation, hypertrophy, fibrosis and dysfunction. Once again, XO
… (MVO2) with no decrease in the rate of left ventricular pressure rise (dP/dT), stroke work or …

… , diabetes mellitus, dilated cardiomyopathy/hypertrophic cardiomyopathy, atrial fibrillation, …
, diabetes mellitus, dilated cardiomyopathy/hypertrophic cardiomyopathy, percutaneous …

… topiroxostat, the commonly prescribed xanthine oxidase inhibitors used in clinical practice, …
to find novel, potent, and safer xanthine oxidase inhibitors.Herbal medications are utilized …

… (NADPH oxidases, xanthine oxidase and mitochondrial … (MI) and impaired left ventricular
systolic function, which are … dysfunction as measured by flow-mediated dilation (FMD) or …